tutorial

Metastatic Hormone-Sensitive Prostate Cancer Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting mHSPC/mCSPC care, covering ADT injection scheduling automation, castration confirmation and testosterone monitoring, cardiovascular risk dashboards, bone health monitoring with DEXA and denosumab, and PSA response tracking toward nadir prediction."

Metastatic Hormone-Sensitive Prostate Cancer Care Tech Platform Monitoring Guide 2026

Overview

Metastatic hormone-sensitive prostate cancer (mHSPC), also called metastatic castration-sensitive prostate cancer (mCSPC), refers to prostate cancer that has spread beyond the prostate to lymph nodes, bone, or visceral organs but retains sensitivity to androgen deprivation therapy (ADT) — the cornerstone of systemic treatment. The disease presents in two clinical scenarios: de novo metastatic disease, where metastases are present at initial diagnosis, and recurrent metastatic disease, where metastasis is detected after prior local therapy (radical prostatectomy or radiation therapy) with rising PSA.

The treatment paradigm for mHSPC underwent a fundamental transformation in the 2016–2022 period with multiple phase III trials demonstrating that ADT alone is insufficient. Intensification regimens — adding a second-generation androgen receptor pathway inhibitor (ARPI) or docetaxel chemotherapy — now constitute the standard of care. Approved combinations include: ADT + abiraterone acetate plus prednisone (LATITUDE, STAMPEDE), ADT + enzalutamide (ARCHES, ENZAMET), ADT + apalutamide (TITAN), ADT + darolutamide + docetaxel (ARASENS), and ADT + docetaxel alone for fit patients with high-volume disease (CHAARTED, STAMPEDE). The choice among these is guided by disease volume (high vs. low, per the CHAARTED criteria), de novo vs. recurrent presentation, comorbidities, and patient preference.

ADT itself — achieved via GnRH agonists (leuprolide, goserelin) or GnRH antagonists (degarelix, relugolix) — is a continuous metabolic intervention that affects cardiovascular risk, bone mineral density, lipid profiles, glucose metabolism, and mood. These systemic effects mandate coordinated monitoring across oncology, primary care, cardiology, and endocrinology. Care technology platforms supporting mHSPC must manage ADT injection scheduling at precise intervals (every 1, 3, 4, or 6 months depending on formulation), confirm castration (serum testosterone < 50 ng/dL), monitor PSA response toward the established nadir at 7 months (a key predictor of long-term outcomes), track cardiovascular metabolic risk, maintain bone health surveillance with DEXA and antiresorptive therapy, and escalate to castration-resistant status when appropriate.

Care Technology Landscape

ADT Injection Scheduling Systems — GnRH agonist injections must be delivered at protocol-defined intervals without delay, as lapses in injection timing can cause testosterone flares. EHR scheduling systems must maintain injection cadence schedules (e.g., leuprolide 22.5 mg every 3 months; leuprolide 45 mg every 6 months; degarelix 240 mg loading then 80 mg every 28 days), generate patient outreach before due dates, and flag overdue injections. Relugolix (oral GnRH antagonist) eliminates injections but requires adherence monitoring via prescription fill rate and patient-reported adherence platforms.

Testosterone Monitoring and Castration Confirmation Platforms — Serum testosterone must be confirmed < 50 ng/dL (castrate level) typically at 3 months after ADT initiation. Failure to achieve castration — termed castration failure or testosterone escape — requires ADT regimen adjustment. Laboratory information systems must route testosterone results to the OIS with automated comparison to the 50 ng/dL castrate threshold, triggering alerts when testosterone rises above this level at any point during therapy.

PSA Response Tracking and Nadir Prediction Engines — PSA at 7 months is a validated surrogate endpoint and predictor of outcomes in mHSPC: a PSA nadir < 0.2 ng/mL at 7 months predicts significantly improved failure-free survival. PSA tracking platforms must display longitudinal PSA trends graphically, flag PSA rises > 25% from nadir confirmed on two measurements (biochemical progression per Prostate Cancer Working Group criteria), and report the 7-month PSA value with comparison to benchmark thresholds.

Cardiovascular Risk Management Dashboards — ADT accelerates atherosclerosis, metabolic syndrome, and QT prolongation (with enzalutamide/apalutamide, via CYP3A4 interactions with anti-arrhythmics). Cardiovascular risk dashboards integrate lipid panel trends, blood pressure, HbA1c, weight, and ECG QTc data to stratify patients by cardiovascular risk and trigger cardio-oncology referrals when risk is elevated.

Bone Health Monitoring Systems — ADT causes accelerated bone loss, increasing fracture risk. DEXA scanning at baseline and at regular intervals (typically every 1–2 years on ADT), FRAX score calculation, and antiresorptive therapy (denosumab 120 mg every 6 months or zoledronic acid annually for osteoporosis) management are standard of care. Bone health platforms must schedule DEXA scans, route results to fracture risk calculators, and trigger denosumab order alerts when T-score thresholds are crossed.

CRPC Escalation Detection Systems — mHSPC progresses to metastatic castration-resistant prostate cancer (mCRPC) when PSA rises or new metastases appear despite castrate testosterone. Clinical informatics platforms must detect and flag CRPC progression (PSA rise on two measurements despite castration + confirmed testosterone < 50 ng/dL) and trigger treatment escalation workflows.

Key Monitoring Metrics

ADT Injection Scheduling and Adherence

Schedule Accuracy

  • ADT injection cadence schedule generated and stored in scheduling system at treatment initiation: creation rate (target: 100%)
  • Injection due dates accurate per formulation-specific interval (monthly, quarterly, 4-monthly, 6-monthly): configuration accuracy audit
  • Patient outreach (SMS/phone/portal) sent ≥ 7 days before each due injection: outreach lead time compliance

Injection Timeliness

  • Injections administered within ±7 days of scheduled date: on-time administration rate (target: > 90%)
  • Injections delayed > 14 days from scheduled date triggering clinical alert: escalation rate
  • Overdue injection (> 21 days past due) triggering urgent nursing outreach: escalation rate

Relugolix Oral Adherence

  • Pharmacy fill rate for relugolix (prescription dispensed before run-out): adherence rate (target: > 90%)
  • Patient-reported adherence survey completion rate (each quarter): completion rate
  • Missed dose pattern (> 3 consecutive missed doses reported) triggering nursing triage call: alert rate

Castration Confirmation and Testosterone Monitoring

Baseline Castration Confirmation

  • Serum testosterone drawn and resulted at 3 months after ADT initiation: lab compliance rate (target: > 95%)
  • Testosterone < 50 ng/dL confirmed at 3 months: achievement rate (track as population metric)
  • Testosterone > 50 ng/dL at 3 months triggering oncologist alert and ADT regimen review: alert generation rate (target: 100%)

Ongoing Surveillance

  • Testosterone surveillance every 6 months during ADT: order compliance rate
  • Testosterone rise > 50 ng/dL at any surveillance timepoint triggering same-day clinical alert: detection rate
  • Time from testosterone escape detection to treatment modification: target ≤ 5 business days

Platform Integration

  • LIS testosterone result routed to OIS with threshold comparison annotation: routing success rate
  • Testosterone trend chart available in oncology encounter view: display availability audit

PSA Response Tracking and Nadir

Longitudinal PSA Monitoring

  • PSA drawn at each clinical visit (every 3 months during first 2 years): order compliance rate (target: > 90%)
  • PSA results displayed as time-trend graph in oncology encounter: display availability
  • PSA nadir value (lowest confirmed PSA on therapy) tracked as a discrete OIS field: capture rate

7-Month Nadir Reporting

  • 7-month PSA value flagged in the PSA trend view with reference range overlay: platform display rate
  • PSA > 4 ng/mL at 7 months triggering oncologist flag (poor-nadir signal): alert generation rate
  • 7-month PSA value included in structured MDT report: MDT documentation rate

Biochemical Progression Detection

  • PSA rise > 25% from nadir AND > 2 ng/mL above nadir on two measurements triggering PCWG3 progression alert: detection rate (target: 100%)
  • Confirmed PSA progression with castrate testosterone flagging CRPC escalation workflow: cascade trigger rate
  • Time from biochemical progression detection to treatment escalation encounter: median and 90th percentile tracking

Cardiovascular Risk Dashboard

Metabolic Monitoring

  • Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) at ADT initiation and every 6 months: order compliance (target: > 85%)
  • HbA1c at ADT initiation and every 6 months: order compliance
  • Blood pressure at every clinical encounter: measurement compliance
  • Body weight and BMI at every clinical encounter: documentation rate

QTc Monitoring for ARPI Patients

  • Baseline ECG before enzalutamide or apalutamide initiation: pre-treatment compliance (target: 100%)
  • QTc > 470 ms (women) or > 460 ms (men) at baseline generating cardiology consultation alert: trigger rate
  • Concurrent QT-prolonging medication co-prescription with enzalutamide/apalutamide triggering pharmacist drug-drug interaction review: DDI alert rate
  • Follow-up ECG at 1 month post-ARPI initiation: compliance rate (for QTc > 450 ms at baseline)

Cardio-Oncology Referral

  • ASCVD risk score ≥ 10% at ADT initiation triggering cardio-oncology consultation flag: CDS trigger rate
  • New major adverse cardiovascular event (MACE) during ADT triggering cardiologist same-day alert: detection rate
  • Statin initiation within 30 days for patients with LDL > 190 mg/dL or ASCVD risk ≥ 10%: treatment compliance

Bone Health Monitoring

DEXA Scheduling

  • Baseline DEXA scan completed within 90 days of ADT initiation: baseline compliance (target: > 85%)
  • Repeat DEXA scheduled at 1–2 year intervals per institutional protocol: scheduling rate
  • DEXA results (T-score, Z-score) routed to OIS structured fields within 5 business days: routing rate

Fracture Risk and Treatment Thresholds

  • FRAX score calculated from DEXA T-score and clinical variables: calculation completeness rate
  • T-score < −2.5 (osteoporosis) triggering denosumab or zoledronic acid order alert: CDS trigger rate (target: 100%)
  • T-score between −1.0 and −2.5 with FRAX 10-year hip fracture ≥ 3% triggering treatment consideration flag: CDS trigger rate

Antiresorptive Therapy Monitoring

  • Denosumab 120 mg Q6 months injection schedule maintained: on-time administration rate (target: > 90%)
  • Calcium (1000–1200 mg/day) and vitamin D (≥ 800 IU/day) supplementation documented: documentation rate
  • Jaw osteonecrosis (ONJ) risk: dental clearance documented before denosumab initiation: pre-treatment compliance

Platform Setup

Observability Architecture for mHSPC Platforms

# Prometheus scrape config for mHSPC care platforms
scrape_configs:
  - job_name: adt_injection_scheduler
    static_configs:
      - targets: ['adt-scheduler.internal:9090']
    scrape_interval: 60s

  - job_name: testosterone_monitoring_router
    static_configs:
      - targets: ['testosterone-router.internal:9090']
    scrape_interval: 30s

  - job_name: psa_tracking_engine
    static_configs:
      - targets: ['psa-tracker.internal:9090']
    scrape_interval: 60s

  - job_name: cardiovascular_risk_dashboard
    static_configs:
      - targets: ['cv-risk-dashboard.internal:9090']
    scrape_interval: 120s

  - job_name: bone_health_platform
    static_configs:
      - targets: ['bone-health.internal:9090']
    scrape_interval: 300s

ADT Injection Due-Date Canary

Validate ADT scheduling and outreach pipelines:

# Pseudocode: ADT injection scheduling canary
def run_adt_canary():
    test_patient_id = "CANARY-MHSPC-ADT-001"
    # Create synthetic ADT injection schedule
    create_adt_schedule(
        patient_id=test_patient_id,
        formulation="leuprolide_22.5mg",
        interval_days=84,  # 3 months
        start_date=today() - 77  # next injection due in 7 days
    )
    # Verify outreach generated within 24 hours
    start = time.now()
    outreach = poll_for_outreach(
        patient_id=test_patient_id,
        outreach_type="adt_injection_reminder",
        timeout=86400  # 24 hours
    )
    latency = time.now() - start
    metrics.record("adt_outreach_latency_seconds", latency)
    if outreach is None:
        page_on_call("mHSPC canary: ADT injection reminder not generated within 24-hour SLA for upcoming due date")

PSA Nadir Tracking and Progression Detection

# Pseudocode: PSA progression alert
PCWG3_RISE_THRESHOLD_PCT = 0.25   # 25% rise from nadir
PCWG3_ABSOLUTE_THRESHOLD = 2.0    # ng/mL above nadir

def monitor_psa_progression(patient_id):
    psa_history = get_psa_history(patient_id, on_adt=True)
    if len(psa_history) < 3:
        return  # Not enough data
    nadir = min(r.value for r in psa_history)
    latest_two = sorted(psa_history, key=lambda r: r.date)[-2:]
    for reading in latest_two:
        rise_pct = (reading.value - nadir) / nadir
        absolute_rise = reading.value - nadir
        if rise_pct >= PCWG3_RISE_THRESHOLD_PCT and absolute_rise >= PCWG3_ABSOLUTE_THRESHOLD:
            confirmed_progression = True
            break
    else:
        confirmed_progression = False
    if confirmed_progression:
        testosterone = get_latest_lab(patient_id, "TESTOSTERONE")
        if testosterone and testosterone.value < 50:
            generate_crpc_progression_alert(patient_id, nadir=nadir, current_psa=latest_two[-1].value)

Testosterone Escape Alert Configuration

-- Alert when testosterone escapes castration in mHSPC patient
CREATE TRIGGER testosterone_escape_alert
AFTER INSERT ON lab_results
FOR EACH ROW
WHEN NEW.test_code = 'TESTOSTERONE'
  AND NEW.value > 50
  AND EXISTS (
    SELECT 1 FROM patients
    WHERE patient_id = NEW.patient_id
      AND diagnosis_code LIKE 'C61%'
      AND adt_status = 'ACTIVE'
  )
BEGIN
  INSERT INTO clinical_alerts (patient_id, alert_type, severity, value, created_at)
  VALUES (NEW.patient_id, 'TESTOSTERONE_ESCAPE', 'P1', NEW.value, NOW());
END;

Denosumab Injection Cadence Monitor

# Monitor denosumab injection adherence for mHSPC patients
DENOSUMAB_INTERVAL_DAYS = 180  # 6 months

def check_denosumab_adherence(patient_id):
    last_injection = get_last_injection(patient_id, drug="denosumab")
    if last_injection is None:
        return  # No prior injection yet
    days_since_last = (today() - last_injection.date).days
    if days_since_last > DENOSUMAB_INTERVAL_DAYS + 14:  # 14-day grace period
        generate_clinical_alert(
            patient_id=patient_id,
            alert_type="DENOSUMAB_OVERDUE",
            severity="P2",
            message=f"Denosumab overdue by {days_since_last - DENOSUMAB_INTERVAL_DAYS} days"
        )

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • ADT injection scheduling system offline; upcoming injection due dates not generating outreach for > 10 patients
  • Testosterone monitoring routing down; escape events (> 50 ng/dL) not generating alerts
  • PSA tracking engine not processing new results; progression detection offline
  • QTc > 500 ms detected in ARPI patient without cardiology alert generation

P2 — Degraded Operation

  • ADT injection overdue rate > 5% of active mHSPC cohort with no outreach attempt logged
  • DEXA scan scheduling compliance < 80% at 12-month interval
  • Cardiovascular metabolic labs (lipids, HbA1c) order compliance < 80%
  • PSA 7-month nadir value not captured in structured OIS field for > 15% of patients
  • Denosumab injection overdue rate > 10% of patients on antiresorptive therapy

P3 — Quality and Compliance

  • CRPC escalation workflow not triggered within 7 days of confirmed biochemical progression: audit flag
  • Dental clearance documentation missing before denosumab initiation > 5% of starts: compliance gap
  • ARPI baseline ECG compliance < 90%: pre-treatment checklist gap

On-Call Escalation

  • Clinical informatics engineer (primary for P1 scheduling and routing system failures)
  • Oncology pharmacist on call (drug-drug interaction alerts and ARPI dose-hold decisions)
  • GU oncology APP on call (P1 testosterone escape and CRPC progression escalations requiring clinical decision)

Notification Channels

  • P1: PagerDuty page + SMS to primary and secondary on-call simultaneously
  • P2: Slack #mhspc-informatics + email to GU oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog; monthly bone health compliance digest to MDT coordinator

Conclusion

Metastatic hormone-sensitive prostate cancer in 2026 is managed with a combination of precise ADT delivery, intensification regimens chosen by volume and disease context, and systematic multi-organ metabolic surveillance — all of which demand sophisticated, well-monitored care technology platforms. The consequences of platform failure are real and measurable: an ADT injection delayed by three weeks due to scheduling system gaps can cause testosterone flare and disease acceleration; a testosterone escape event undetected for two months means two months of uncontrolled androgen-driven proliferation; a DEXA scan missed for three years means preventable hip fractures.

Engineering teams responsible for mHSPC informatics should prioritize ADT injection scheduling canary tests, automated testosterone escape detection, PSA progression alerting calibrated to PCWG3 criteria, and bone health monitoring pipelines with denosumab cadence checks. With these systems operating reliably and observably, care technology enables the coordinated multi-disciplinary management that gives mHSPC patients the best chance of a durable response and a protected quality of life on long-term androgen deprivation.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles